Pharmacotherapy of diabetes mellitus in patients with heart failure – a nation-wide analysis of contemporary treatment

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F23%3A10157628" target="_blank" >RIV/00098892:_____/23:10157628 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/23:00129948

Result on the web

<a href="https://biomed.papers.upol.cz/artkey/bio-202302-0012_pharmacotherapy-of-diabetes-mellitus-in-patients-with-heart-failure-a-nation-wide-analysis-of-contemporary-tr.php" target="_blank" >https://biomed.papers.upol.cz/artkey/bio-202302-0012_pharmacotherapy-of-diabetes-mellitus-in-patients-with-heart-failure-a-nation-wide-analysis-of-contemporary-tr.php</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2021.069" target="_blank" >10.5507/bp.2021.069</a>

Result language

angličtina

Original language name

Pharmacotherapy of diabetes mellitus in patients with heart failure – a nation-wide analysis of contemporary treatment

Original language description

Aim. Retrospective national sub-analysis of antidiabetic pharmacotherapy in patients with diabetes mellitus (DM) and heart failure (HF) based on data reported to the National Register of Paid Health Services in the Czech Republic between 2012–2018. Methodology and Results. In 2012, there were 75,022 patients with HF and DM (i.e. 42.5% of patients with HF), 6 years later 117,265 (i.e. 41.0% of HF patients in 2018). The most represented antidiabetic drug was metformin (45.6%). Of the insulins and analogues, glargine showed the largest positive trend (5.8% 2012; 14.8% 2018). Empagliflozin was the most prescribed SGLT-2 inhibitor (1.8% in 2018). A decrease in prescribing was observed for saxagliptin (0.5% 2012;0.1% 2018) and for sulfonylurea derivates – gliclazide (13.0% 2012; 10.3% in 2018) and glimepiride (12.9% 2012; 9.0% 2018). Linagliptin was the most prescribed dipeptidyl peptidase inhibitor (0.7% 2012; 6.8% 2018). Conclusion. In the Czech Republic, between 2012 and 2008, there was an increase in prevalence of patients with heart failure and concomitant diabetes mellitus, their proportion being similar. In correspondence with other registries, metformin was used mostly. A positive trend was observed in prescription of DDP-4 and SGLT-2 inhibitors, while there was a significant decrease in patients taking sulfonylureas.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Biomedical Papers

ISSN

1213-8118

e-ISSN

1804-7521

Volume of the periodical

167

Issue of the periodical within the volume

2

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

8

Pages from-to

177-184

UT code for WoS article

000731342200001

EID of the result in the Scopus database

2-s2.0-85162786092